Directions for use and doses
- Maintaining the luteal phase during the use of assisted reproduction methods: starting from the day of embryo transfer, the gel is used in a dose of 1.125 g (90 mg of progesterone - 1 applicator) and is administered intravaginally daily. If pregnancy occurs, therapy is continued until 12 weeks or for 10-12 weeks from the moment of confirmed pregnancy.
- Secondary amenorrhea, dysfunctional uterine bleeding caused by progesterone deficiency: 1.125 g of gel (90 mg of progesterone) is administered intravaginally every other day from 15 to 25 days of the cycle. If necessary, the dose can be reduced or increased.
- Hormone replacement therapy in postmenopause (in combination with estrogen drugs): 90 mg (1 applicator) is administered 2 times a week.
Carefully read the instructions for the rules of drug administration.
Crinon suppositories and gel for IVF
One of the methods for increasing the effectiveness of the in vitro fertilization protocol is the administration of hormonal therapy. During this mandatory stage, thanks to the administration of medications, favorable conditions are created in the uterus for embryo transfer. Such medications include " Crinon
"(
gel
and suppositories).
"Сrinone": the effect of the drug
The successful course of pregnancy depends on progesterone. It is responsible for the readiness of the endometrium in the uterus for implantation and reduces the chances of embryo rejection during natural fertilization. When using the IVF method, such changes do not occur due to the continuation of menstruation, as a result of which on certain days there is a decrease in progesterone concentration and endometrial rejection. Therefore, in such cases, progesterone medications are prescribed for successful conception.
The drug "Crinone" is available in the form of suppositories and gel. If the first form is more familiar to most women, the second is popular due to its ease of use and speed of absorption. The hormone contained in Crinone thickens the endometrium, provokes the transition of the mucous membranes of the uterus into the secretion phase and weakens the contraction of the uterine muscles and tubes.
Thus, the drug brings the level of progesterone after IVF to a concentration characteristic of natural fertilization.
Dosage and methods of application
The drug is taken immediately after embryo transfer. One dose of the gel substrate or one Crinona suppository is inserted into the vagina. The gel is dosed in applicators containing 1.125 g (equal to 90 g of progesterone). The Krinona documentation (instructions for use) states that it should be administered once a day before bedtime for better absorption and active action.
During physical activity, the remains of the gel or suppository may come out in the form of discharge (brown, beige, pink)
– normal), which will weaken the effect.
In case of successful conception with IVF,
“
Crinon
” is taken until the 12th week of gestation.
Contraindications and side effects
Krinon should be taken only on the recommendation of a doctor. Contraindications include:
- diseases of the vascular system;
- porphyria;
- lactation period;
- uncompleted abortion and much more.
Certain side effects
, among which:
- stomach pain;
- depression;
- soreness of the mammary glands;
- spotting;
- allergic reactions;
- headache.
We can see that Crinon is a real panacea for those women whose infertility is caused by endocrine disorders or insufficient thickness of the endometrium.
Crinone (INN progesterone)
Crinone (INN progesterone) is a hormone of the corpus luteum. Causes a transition of the uterine mucosa from the proliferation phase, caused by the action of FSH, to the secretory phase. Reduces the excitability and contractility of the muscles of the uterus and fallopian tubes. Progesterone inhibits the secretion of hypothalamic release factors of FSH and LH, inhibits the formation of gonadotropic hormones in the pituitary gland and inhibits ovulation. In vaginal gel, progesterone is included in a polymer delivery system that binds to the vaginal mucosa and provides continuous release of progesterone for at least 3 days. When using vaginal gel in doses corresponding to 90 mg of progesterone, Cmax is achieved after 6 hours and is 11 ng/ml.
Metabolism and excretion: T1/2 - 34-48 hours. Progesterone is metabolized mainly in the liver. Intravaginal use significantly reduces the “first pass” effect through the liver. The main metabolite, 3-α, 5-β-pregnanediol, is excreted in the urine.
Indications for use: maintaining the luteal phase, incl. after using assisted reproductive technologies; secondary amenorrhea or dysfunctional uterine bleeding caused by progesterone deficiency; hormone replacement therapy.
Method of administration and dosage To maintain the luteal phase during the use of assisted reproductive techniques, starting from the day of embryo transfer, the gel is used in a dose of 1.125 g (90 mg of progesterone - 1 applicator) and is administered intravaginally daily for 30 days from the moment of clinically confirmed pregnancy. For secondary amenorrhea, dysfunctional uterine bleeding caused by progesterone deficiency, 1.125 g of gel (90 mg of progesterone) is administered intravaginally every other day from day 15 to day 25 of the cycle. If necessary, the dose can be reduced or increased. When carrying out hormone replacement therapy, the drug in a dose of 90-180 mg (1-2 applicators) is administered 1-2
Rules for using the drug The patient should be informed about the need to strictly follow the recommendations for use of the drug. To ensure hygienic conditions and ease of use, Crinon is packaged in a disposable applicator, which should be thrown away after use. Hold the applicator at the top between your thumb and forefinger. Shake the applicator like a medical thermometer so that the gel moves to the lower end of the applicator. Hold the applicator by the top flat end. Remove the break-off cap from the opposite end by turning it. Do not press on the air container. The patient should be in a supine position with knees slightly bent. Carefully insert the lower end of the applicator into the vagina. Squeeze the air container firmly so that the gel from the applicator enters the vagina. Although some gel remains in the applicator, the dose is fully administered. Now you can throw away the applicator with the remaining gel. Progesterone will be absorbed slowly and over a long period of time.
Side effects From the central nervous system: headache, drowsiness. From the digestive system: abdominal pain. From the reproductive system: soreness of the mammary glands; rarely - intermenstrual bleeding, irritation of the vaginal mucosa at the site of application.
Contraindications: vaginal bleeding of unknown etiology; porphyria; malignant tumors of the genital organs or mammary glands; acute thrombosis or thrombophlebitis, thromboembolic diseases; acute cerebrovascular accident (including history); non-developing pregnancy; lactation; hypersensitivity to the components of the drug.
Use of the drug during pregnancy and lactation Crinon should not be used during pregnancy, with the exception of use in early pregnancy during assisted reproduction methods. Contraindicated for use during lactation (breastfeeding).
Special instructions The composition of the drug Krinon includes sorbic acid, which can cause a local skin reaction (contact dermatitis). During long-term therapy, it is necessary to conduct regular gynecological examinations in order to exclude the possibility of developing endometrial hyperplasia. When using Crinon, the level of human chorionic gonadotropin should be determined or an ultrasound should be performed to prevent the occurrence of a threatened abortion. Prescribe the drug with caution in case of liver dysfunction.
In case of sudden bleeding, as in the case of irregular vaginal bleeding, a non-functional cause should be excluded. If vaginal bleeding of unknown etiology occurs, appropriate examination should be performed.
The drug is prescribed with caution and under constant monitoring to patients with epilepsy, migraine, asthma, chronic heart failure, and impaired renal function (due to possible fluid retention in the body).
Patients with a history of depression should be closely monitored and the drug should be discontinued if depression worsens.
During the use of estrogens and progestogens, some patients may experience a decrease in glucose tolerance (the mechanism of this disorder is unknown). While using the drug, patients with diabetes mellitus should be closely monitored.
Patients using Crinon should be careful when engaging in activities that require increased attention (as a feeling of fatigue may occur). Drinking alcohol may increase this effect.
Overdose: Currently, no cases of overdose of the drug Crinon have been reported.
Drug interactions: the use of Crinon together with other intravaginal drugs is not recommended.
Storage conditions: the drug should be stored out of the reach of children at a temperature not exceeding 25°C; do not freeze. Shelf life: 3 years. The drug is available with a prescription.
Project manager: Elena Shoina +7 [email protected]
Section: Drugs for ART | Manufacturer: Serono Print | ↑ Up
Crinon gel (vaginal tube. 90 mg/dose 1.125 g pack. combo. No. 15)
A country
Great Britain, United Kingdom
Country of origin may vary depending on product batch. Please check with the operator for detailed information when confirming your order.
Active substance
Progesterone
Compound
1 applicator contains: progesterone 90 mg.
Excipients: glycerol, liquid light paraffin, hydrogenated palm oil glyceride, carbomer 974P, sorbic acid, polycarbophil, sodium hydroxide, purified water. Vaginal gel is homogeneous, white or almost white in color, soft consistency, with a specific odor.
pharmachologic effect
Gestagen. Progesterone is a hormone of the corpus luteum. Causes a transition of the uterine mucosa from the proliferation phase, caused by the action of FSH, to the secretory phase. Reduces the excitability and contractility of the muscles of the uterus and fallopian tubes. Progesterone inhibits the secretion of hypothalamic release factors of FSH and LH, inhibits the formation of gonadotropic hormones in the pituitary gland and inhibits ovulation. Crinon® Vaginal Gel incorporates progesterone into a polymer delivery system that binds to the vaginal mucosa and provides continuous release of progesterone for at least 3 days.
Indications for use
— maintaining the luteal phase during the use of auxiliary methods of reproduction; - secondary amenorrhea, dysfunctional uterine bleeding caused by progesterone deficiency; - hormone replacement therapy in postmenopause (in combination with estrogen drugs).
Mode of application
Maintaining the luteal phase during the use of assisted reproduction methods Starting from the day of embryo transfer, the gel is used in a dose of 1.125 g (90 mg of progesterone - 1 applicator) and is administered intravaginally daily. If pregnancy occurs, therapy is continued until 12 weeks or for 10-12 weeks from the moment of confirmed pregnancy. Secondary amenorrhea, dysfunctional uterine bleeding caused by progesterone deficiency 1.125 g of gel (90 mg of progesterone) is administered intravaginally every other day from 15 to 25 days of the cycle. If necessary, the dose can be reduced or increased. Hormone replacement therapy in postmenopause (in combination with estrogen drugs) 90 mg (1 applicator) is administered 2 times a week. Rules for using the drug The patient should be informed about the need to strictly follow the recommendations for use of the drug. To ensure hygienic conditions and ease of use, Krynon® is packaged in a disposable applicator, which should be thrown away after use. 1. Take the applicator, holding it tightly at the top between your thumb and forefinger. Shake the applicator like a medical thermometer so that the gel moves to the lower end of the applicator. 2. Hold the applicator by the top flat end of the air container. Remove the break-off cap from the opposite end by turning it. Do not press on the air container. 3. The applicator can be inserted either in a sitting position or in a lying position with slightly bent knees. Carefully insert the lower end of the applicator into the vagina. 4. Squeeze the air container firmly so that the gel from the applicator enters the vagina. Although some gel remains in the applicator, the dose is fully administered. Now you can throw away the applicator with the remaining gel. Crinone® coats the vaginal mucosa, providing prolonged release of progesterone.
Interaction
The use of Crinon® together with other intravaginal agents is not recommended.
Side effect
From the side of the central nervous system: headache, drowsiness. From the digestive system: abdominal pain. From the reproductive system: soreness of the mammary glands, intermenstrual bleeding, irritation of the vaginal mucosa and other local reactions of moderate severity in the area of application. Allergic reactions: hypersensitivity reactions are possible, usually manifested in the form of a skin rash.
Contraindications
- vaginal bleeding of unknown etiology; - acute porphyria; - malignant tumors of the genital organs or mammary glands or suspicion of their presence; - acute thrombosis or thrombophlebitis, thromboembolic diseases; - acute cerebrovascular accident (including history); - incomplete abortion; - period of breastfeeding; - hypersensitivity to the components of the drug. The drug should be used with caution in case of arterial hypertension, chronic renal failure, cardiovascular failure, diabetes mellitus, bronchial asthma, epilepsy, migraine, depression, hyperlipoproteinemia.
special instructions
Particular attention should be paid to the possible appearance of early symptoms of thrombotic disorders (thrombophlebitis, cerebrovascular accidents, pulmonary embolism and retinal thrombosis). If a symptom is detected that indicates these disorders or even suggests their presence, you should immediately stop taking the drug. Patients with any risk factors for thrombotic disorders should be closely monitored. During long-term treatment, regular gynecological examinations are necessary to exclude the possibility of developing endometrial hyperplasia. Physical examination before starting therapy should include assessment of the condition and development of the mammary glands and pelvic organs, as well as a cervical smear (Papanicolaou test). In order to prevent the possibility of incomplete abortion when using the drug Krinon®, the level of human chorionic gonadotropin should be determined or an ultrasound examination should be performed. Use with caution in case of liver dysfunction. In cases of breakthrough bleeding, as in all cases of irregular vaginal bleeding, organic pathology should be excluded. In case of vaginal bleeding of unknown etiology, appropriate examination should be carried out. Because progestogens have the ability to retain fluid in the body; patients with diseases such as epilepsy, migraine, bronchial asthma, cardiovascular failure, and renal impairment should be closely monitored. Patients with a history of depression should be closely monitored and treatment should be interrupted if depression worsens. A small number of patients receiving estrogen-progestogen therapy may experience decreased glucose tolerance. The mechanism of this disorder is not known. In this regard, patients suffering from diabetes mellitus should be closely monitored during treatment with progesterone. Crinon® contains sorbic acid, which can cause a local skin reaction (contact dermatitis). Effect of the drug on the ability to drive a car and operate other mechanisms Krinon® has a weak or moderate effect on the ability to drive a car and operate machinery. Because When using the drug Crinon®, you may feel tired or drowsy; caution is required when driving a car and other mechanisms. The use of alcohol may enhance this effect.
Dispensing conditions in pharmacies
On prescription
